{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:22:15Z","timestamp":1790490135805,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clml.2017.06.034","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T13:17:46Z","timestamp":1498828666000},"page":"734-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma"],"prefix":"10.1016","volume":"17","author":[{"given":"Gergely","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin Piroska","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Kos\u00f3czki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Meggyesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Balassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"K\u00f6vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Tegze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-0109","authenticated-orcid":false,"given":"Gergely","family":"Szombath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Tordai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-8140","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Homolya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.034_bib1","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.034_bib2","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.034_bib3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.034_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm2630","article-title":"Molecular mechanisms of proteasome assembly","volume":"10","author":"Murata","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2017.06.034_bib5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.034_bib6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1134\/S000629790913001X","article-title":"Proteasome system of protein degradation and processing","volume":"74","author":"Sorokin","year":"2009","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.clml.2017.06.034_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80929-0","article-title":"The proteasome: paradigm of a self-compartmentalizing protease","volume":"92","author":"Baumeister","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clml.2017.06.034_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.06.034_bib9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1271\/bbb.130290","article-title":"Role of nuclear localization of PSMB1 in transcriptional activation","volume":"77","author":"Yamauchi","year":"2013","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.clml.2017.06.034_bib10","doi-asserted-by":"crossref","first-page":"25545","DOI":"10.1074\/jbc.M109.079152","article-title":"Identification of glucose transporter 4 knockdown-dependent transcriptional activation element on the retinol binding protein 4 gene promoter and requirement of the 20 S proteasome subunit for transcriptional activity","volume":"285","author":"Inoue","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2017.06.034_bib11","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","article-title":"Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.034_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.034_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth759","article-title":"Activity probe for in\u00a0vivo profiling of\u00a0the specificity of proteasome inhibitor bortezomib","volume":"2","author":"Berkers","year":"2005","journal-title":"Nat Methods"},{"key":"10.1016\/j.clml.2017.06.034_bib14","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1182\/blood-2012-05-426924","article-title":"Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone","volume":"120","author":"Lichter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.034_bib15","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1078-0432.CCR-12-3069","article-title":"Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab","volume":"19","author":"Coiffier","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.06.034_bib16","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.034_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.034_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.034_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.034_bib20","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.034_bib21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.034_bib22","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.034_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.1986.tb07538.x","article-title":"Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma","volume":"63","author":"Monconduit","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.034_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.06.034_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A\u00a0global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.06.034_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/10428190902895780","article-title":"Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells","volume":"50","author":"Dong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.034_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/auto.6.1.10323","article-title":"Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells","volume":"6","author":"Periyasamy-Thandavan","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.clml.2017.06.034_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3109\/10428194.2010.483302","article-title":"Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial","volume":"51","author":"Goy","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.034_bib29","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/0008-5472.CAN-09-4428","article-title":"Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.034_bib30","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","article-title":"RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5","volume":"117","author":"Zhu","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730633X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730633X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:27Z","timestamp":1761870567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501730633X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S215226501730633X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.034","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}